# Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

> **NCT06004661** · PHASE2 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 20 (estimated)

## Conditions studied

- Metastatic Castration-Resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** AAA617
- **DRUG:** 68Ga-PSMA-11

## Key facts

- **NCT ID:** NCT06004661
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-04
- **Primary completion:** 2026-06-17
- **Final completion:** 2026-06-17
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06004661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06004661, "Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06004661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*